Skip to main content

Table 3 Univariate and multivariate analyses of pCR against various characteristics in breast cancer patients who received neoadjuvant chemotherapy

From: S100A6 inhibits MDM2 to suppress breast cancer growth and enhance sensitivity to chemotherapy

Variable

pCR rate (%)

Univariate analysis P value

Multivariate analysis

P value

S100A6 (high/low)

41.8%/11.5%

 < 0.0001

0.010

MDM2 (high/low)

15.4%/33.8%

 < 0.0001

0.215

Size (pT1-2/pT3-4)

27.2%/27.0%

0.680

0.757

Histological grade (I–II/III)

24.7%/33.3%

0.300

0.543

LN metastasis (posi/neg)

27.7%/25.0%

0.882

0.679

MIB (< 10%/ ≥ 10%)

12.5%/29.7%

0.177

0.664

ERα (posi/neg)

19.1%/38.6%

0.045

0.798

PR (posi/neg)

21.3%/34.8%

0.188

0.294

Her2 (posi/neg)

47.8%/21.4%

0.008

0.001

Molecular subtype (TNBC/others)

44.4%/21.3%

0.046

0.011